All eyes are on the scheduled release of BioNTech's fourth-quarter and full-year 2025 financial results, set for March 10, 2026. The accompanying conference call will occur during a period of intense ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...
Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging ...
Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...
BioNTech SE BNTX has filed a patent infringement lawsuit against Moderna Inc. MRNA, alleging that Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, relies on proprietary technology developed and ...
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...
Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results